Cassava Sciences Inc
Save
–
Market cap
–
Current P/E
18.98x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Similar securities
Based on sector and market capitalization
Report issue